Board summary
Key figures
43,616
Registered population
61.6% aged 18–64
18.0%
Aged 65+
ICB 14.9% · England 17.9%
32.1%
In IMD quintile 1
ICB 40.7% · England 21.0%
~17,953
Core20 residents (est.)
Resident basis; registered basis ~14,585 · see page 3
7,827
Hypertension register
+3.60% in 3 yrs · England +5.60%
392
SMI register
16.7% of Tameside (LAD)'s
1,252
COPD register
Reviews +5.94% in 3 yrs
Forecast to 2030
8,745
Hypertension patients, 2030
+918 on today
70.5%
QRISK ≥20% on statins, 2030
+0.99pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Three-year change trails England across 15 measures.
Of 25 compared measures, 15 trail England over three years, including heart failure reviews (-4.0% versus +8.7%) and hypertension control (-1.0% versus +3.6%).
Wide practice spreads in access and deprivation.
Phone contact ease spans 28.4 pp (Pike Medical Practice 63.2% to St. Andrew's House Surgery 91.6%), while Core20 patient share spans 53.9 pp.
Current cardiovascular control exceeds England averages.
Hypertension treated to target reaches 73.6% (England 70.3%), alongside higher heart failure review coverage (82.9% versus 78.5%) and QRISK lipid therapy (68.4% versus 63.6%).
Population, age and ethnicity
Patients aged 65+ represent 18.0% of the list alongside 509 local care-home beds
Across 43,616 registered patients, 18.0% (7,848 patients) are aged 65+, above Tameside (LAD) (16.4%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Working-age adults (18–64) comprise 61.6% (26,855 patients; LAD 62.3%, ICB 63.3%, England 62.7%), and children aged 0–17 represent 20.4% (8,913 patients; LAD 21.3%, ICB 21.8%, England 19.6%). Recorded Gypsy or Irish Traveller and Roma groups are both 0.0%. List size is projected to grow 1.9% by 2030 (LAD 1.4%, ICB 1.6%, England 2.3%; unverified methodology). Observation periods for list and age distributions were not supplied.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Tameside (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tameside LA) | 2,047 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tameside LA) | 1,045 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tameside LA) | 32.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share reaches 32.1% overall but ranges by 53.9 pp across practices
The PCN Core20 share is 32.1%, above England (21.0%) but below Tameside (LAD) (40.9%) and NHS Greater Manchester Integrated Care Board (40.7%), with an average IMD decile of 4.3 (England 5.5 decile). Before targeting, weighted practice share (33.4%) differs from the PCN figure by 1.36 pp. Across practices, concentration spans 53.9 pp, from 6.6% at Pike Medical Practice to 60.5% at King Street Medical Centre, while Staveleigh Medical Centre holds the largest volume at 3,535 estimated Core20 patients. Outreach should balance high-concentration practices with high-volume lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
392
SMI register
0.90% recorded prevalence
289
Learning disability register
0.66% recorded prevalence
13
Care homes, 509 beds
In the PCN catchment
9.7%
Provide unpaid care
Tameside (LAD), Census 2021
Registers record 289 patients with learning disabilities (0.7%; LAD 0.7%, ICB 0.6%, England 0.6%) and 392 with severe mental illness (0.9%; LAD 1.0%, England 1.0%). Catchment care homes hold 509 beds across 13 sites. At borough level, Census data models an unpaid-carer ceiling of 4,231, while autumn 2025 rough sleeping was 16.
Severe mental illness: physical health checks
Recorded SMI checks exceed England: blood pressure checks reach 88.9% (England 83.4%) and BMI reaches 85.9% (England 82.1%). However, smoking cessation offers for patients with certain conditions fell 2.7 pp over 2023 to 2025 (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,827
Hypertension register
+3.60%
Register growth, 3 yrs
Tameside (LAD) +5.50% · England +5.60%
+0.86pp
BP control, under 80
≤140/90 · +2.70pp aged 80+
+918
More patients by 2030
Forecast 8,745 (19.30%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.0% (7,827 patients), above Tameside (17.4%), the ICB (14.4%) and England (15.2%). Current control exceeds benchmarks: 73.6% of hypertensive patients are treated to target (England 70.3%) and 71.1% under age 80 achieve blood pressure at or below 140/90 mmHg (England 67.8%). However, three-year control trends trail national progress: treatment to target fell 1.0% (England +3.6%) and under-80 control rose +1.2% (England +3.2%), which could reflect recall pressure (unverified locally; a recall audit would test this). Register growth (+3.6%) also trailed England (+5.6%). Higher current control alongside trailing three-year progress suggests prioritising blood pressure recall reviews to sustain clinical control.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 68.4% (Tameside 69.2%, ICB 67.0%, England 63.6%). However, three-year treatment growth of +1.5% trails England (+6.2%). Favourable current coverage alongside slower uptake growth indicates the PCN could prioritise structured cardiovascular risk reviews to identify eligible patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 87,438 | £2.10 | £1.94 | £1.86 | £183,620 |
| Cardiovascular (all), 2025 | 123,460 | £2.99 | £3.15 | £3.33 | £369,145 |
In 2026, the PCN prescribed 87,438 items for lipid-regulating drugs at £2.10 per item (Tameside £2.01, ICB £1.94, England £1.86), spending £20,985 more than at England's unit cost. Higher unit costs highlight an opportunity to review formulary choices without compromising clinical treatment thresholds.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.21%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.52%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.0% (3,260 patients; England 6.6%), with 5–19 asthma prescribing at 2,086 rate per 1,000 (England 1,488 rate). Annual asthma reviews cover 64.5% (England 65.7%), leaving an estimated 1,157 patients unreviewed. Conversely, COPD prevalence is 2.9% (1,252 patients; England 1.9%) with reviews reaching 79.3% (England 76.4%). Higher youth prescribing alongside lower review coverage may reflect recall pressure (unverified locally; a recall audit would test this).
Cancer register and children's immunisation
The cancer register records 1,716 patients (3.9% prevalence; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 24 months reaches 98.8% (England 92.2%). At age 5, MMR dose 1 reaches 94.9%, while MMR dose 2 is 86.3% (8.6 pp lower; 8.7 pp below the 95.0% target) and the 4-in-1 booster is 82.1% (12.9 pp below target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of staged cancers (6,491 of 11,679) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% of all 16,492 registered cancers. Closing this gap across the ICB would require an estimated 2,268.2 additional early-stage cases annually. While PCN cervical screening reaches 73.5% (England 66.8%), three-year change is -1.5% (England -1.0%) and coverage falls to 66.3% at King Street Medical Centre. Staging reflects wider system diagnostic pathways rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Tameside and Glossop Integrated Care NHS Foundation Trust, 62-day referral to treatment was 76.7676%, trailing the 85.0% standard by 8.2 pp (NHS Greater Manchester Integrated Care Board reached 75.7262%, 9.3 pp below standard). The trust met the 28-day faster diagnosis standard at 82.4757% (7.5 pp above the 75.0% standard; ICB 79.5261%) and the 31-day combined standard at 96.25% (0.2 pp above the 96.0% standard; ICB 96.4937%). While the PCN cancer register grew +15.2% over 2023 to 2025 (England +9.0%) to 1,716 patients, these waiting times describe trust and ICB performance rather than PCN delivery.
| Pathways within standard (%) | Tameside and Glossop Integrated Care | Northern Care Alliance | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.48 | 75.20 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.25 | 94.54 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.77 | 78.65 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Tameside and Glossop Integrated Care | Northern Care Alliance | Manchester | England |
|---|---|---|---|---|
| MRI | 0.00 | 5.09 | 11.68 | 21.40 |
| CT | 0.18 | 4.10 | 14.66 | 9.92 |
| Echocardiography | 0.00 | 31.48 | 4.91 | 28.48 |
| Colonoscopy | 1.51 | 40.04 | 4.51 | 30.83 |
| Gastroscopy | 5.45 | 36.48 | 29.35 | 29.02 |
| All 15 DM01 tests | 0.80 | 15.71 | 8.98 | 23.14 |
| Community services activity | Tameside residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 50,685 | 573,310 |
| Referrals | 9,450 | 94,470 |
| Patients with a contact | 15,790 | 183,535 |
Community services (residents of Tameside), Jun 2026 (provisional). In the Community Services Dataset (Jun 2026 (provisional)), 52.1% of community contacts for borough residents were with adults aged 65+ (26,410 of 50,685 contacts). Across the PCN, 18.0% of registered patients are aged 65+ (7,848 patients) and 1,716 are on the cancer register (3.9%), though community contacts were not captured at PCN level.
Practice variation and patient experience
Vaccination achievement spans 74.8 pp and phone access spans 28.4 pp across practices
In 2025/26, overall QOF achievement was 89.0% at Millbrook Medical Practice, while achievement at Staveleigh Medical Centre was 97.2%; England averaged 92.5%. Across England, vaccination and immunisation domain achievement was 55.2%. In that domain, achievement was 16.4% at Millbrook Medical Practice, while achievement was 91.2% at Mossley Medical Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| St. Andrew's | 106 | 44.2 | 91.6% | 73.3% | 93.8% |
| King Street | 97 | 60.5 | 82.8% | 72.7% | 89.8% |
| Grosvenor | 111 | 35.4 | 85.9% | 81.0% | 89.7% |
| Lockside | 127 | 26.9 | 85.3% | 73.0% | 89.3% |
| Town Hall Surgery | 96 | 46.7 | 74.6% | 68.4% | 87.0% |
| Staveleigh | 103 | 42.7 | 80.3% | 73.3% | 86.4% |
| Millbrook Medical | 93 | 6.8 | 63.2% | 70.9% | 83.0% |
| Mossley Medical | 90 | 15.2 | 67.3% | 71.8% | 81.9% |
| Pike Medical | 95 | 6.6 | 63.2% | 71.6% | 75.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 measures trail England's three-year change, led by chronic disease reviews
Across 25 compared measures, 15 trailed England's three-year change (2023 to 2025). Gaps were widest in chronic disease processes, led by heart failure reviews (-4.0% versus +8.7% in England) and non-frail diabetes HbA1c control (-1.8% versus +4.4%), alongside slower register growth in learning disability (+0.6% versus +5.4%). Conversely, physical health checks for severe mental illness outpaced national trends, including blood pressure checks (+7.7 pp versus +4.4 pp). These review lags may reflect recall pressures (unverified locally; a recall audit would test this).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Diabetes HbA1c control
Learning disability register
QRISK statin treatment
Hypertension treated to target
Breast screening (53-70)
BP check (SMI)
COPD reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tameside (LAD) | Asset | PCN | Tameside (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (509 beds) | n/a | Schools (catchment) | 49 | n/a |
| Children's centres | 5 | 16 | Places of worship | 31 | 104 |
| Libraries | 2 | 7 | Homelessness support (VCS) | n/a | 2 |
| Primary schools (LA maintained) | 9 | 22 | Primary academies | 8 | 46 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Standardised asthma review and inhaler recall
Annual asthma reviews cover 64.5% of 3,260 registered patients (England 65.7%, ICB 66.2%), leaving an estimated 1,157 patients without a recorded review in 12 months. For discussion: the PCN could run a standardised recall search and offer after-school or school-holiday review slots alongside inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Cardiovascular and chronic disease recall audit
Across 25 measures, 15 trail England's 2023 to 2025 change, led by heart failure reviews (-4.0% versus +8.7%), non-frail diabetes HbA1c <= 58 mmol/mol (-1.8% versus +4.4%), and hypertension control (-1.0% versus +3.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school MMR2 and booster recall
In Q1 2025/26 (cohort 117), age-5 MMR1 reaches 94.9%, but MMR2 is 86.3% (8.6 pp lower; 8.7 pp below the 95.0% standard) and the 4-in-1 booster is 82.1% (12.9 pp below standard). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home MDT capacity review (p2) | Count of care home beds in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Standardised asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Cardiovascular and chronic disease recall audit (p12) | Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
